FGP
KNSA icon

Freestone Grove Partners’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Freestone Grove Partners’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$295K Sell
4,615
-12,045
-72% -$625K ﹤0.01% 760
2026
Q1 		$802K Buy
+16,660
New +$738K 0.01% 517

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Freestone Grove Partners's KNSA Position: Q2 2026 in Review

Freestone Grove Partners reduced its Kiniksa Pharmaceuticals (KNSA) stake by 72% in Q2 2026, selling an estimated $625K and leaving 4,615 shares worth $295K. The position accounts for ﹤0.01% of the portfolio, ranked #760.

Freestone Grove Partners first reported a position in KNSA in Q1 2026 and has held it in 2 quarters since. The position peaked at $802K in Q1 2026. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Freestone Grove Partners held 4,615 shares of Kiniksa Pharmaceuticals worth $295K as of Q2 2026.
  • Freestone Grove Partners sold 12,045 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $625K.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #760 holding.
  • Freestone Grove Partners first reported a position in Kiniksa Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Freestone Grove Partners's Kiniksa Pharmaceuticals position peaked at $802K in Q1 2026.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.